Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits

The complex mechanism of blonanserin action involving D3-5-HT2A and D 1-NMDA receptors in the mPFC

Hirotake Hida, Akihiro Mouri, Kentaro Mori, Yurie Matsumoto, Takeshi Seki, Masayuki Taniguchi, Kiyofumi Yamada, Kunihiro Iwamoto, Norio Ozaki, Toshitaka Nabeshima, Yukihiro Noda

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Blonanserin differs from currently used serotonin 5-HT 2A/dopamine-D 2 receptor antagonists in that it exhibits higher affinity for dopamine-D 2/3 receptors than for serotonin 5-HT 2A receptors. We investigated the involvement of dopamine-D 3 receptors in the effects of blonanserin on cognitive impairment in an animal model of schizophrenia. We also sought to elucidate the molecular mechanism underlying this involvement. Blonanserin, as well as olanzapine, significantly ameliorated phencyclidine (PCP)-induced impairment of visual-recognition memory, as demonstrated by the novel-object recognition test (NORT) and increased extracellular dopamine levels in the medial prefrontal cortex (mPFC). With blonanserin, both of these effects were antagonized by DOI (a serotonin 5-HT 2A receptor agonist) and 7-OH-DPAT (a dopamine-D 3 receptor agonist), whereas the effects of olanzapine were antagonized by DOI but not by 7-OH-DPAT. The ameliorating effect was also antagonized by SCH23390 (a dopamine-D 1 receptor antagonist) and H-89 (a protein kinase A (PKA) inhibitor). Blonanserin significantly remediated the decrease in phosphorylation levels of PKA at Thr 197 and of NR1 (an essential subunit of N-methyl-D-aspartate (NMDA) receptors) at Ser 897 by PKA in the mPFC after a NORT training session in the PCP-administered mice. There were no differences in the levels of NR1 phosphorylated at Ser 896 by PKC in any group. These results suggest that the ameliorating effect of blonanserin on PCP-induced cognitive impairment is associated with indirect functional stimulation of the dopamine-D 1-PKA-NMDA receptor pathway following augmentation of dopaminergic neurotransmission due to inhibition of both dopamine-D 3 and serotonin 5-HT 2A receptors in the mPFC.

Original languageEnglish
Pages (from-to)601-613
Number of pages13
JournalNeuropsychopharmacology
Volume40
Issue number3
DOIs
Publication statusPublished - 01-01-2015
Externally publishedYes

Fingerprint

Phencyclidine
Memory Disorders
Prefrontal Cortex
N-Methyl-D-Aspartate Receptors
Dopamine
olanzapine
Cyclic AMP-Dependent Protein Kinases
Receptor, Serotonin, 5-HT2A
Serotonin
Serotonin 5-HT2 Receptors
Receptors, Serotonin, 5-HT3
Recognition (Psychology)
blonanserin
Vision Disorders
Protein Kinase Inhibitors
Synaptic Transmission
Schizophrenia
Animal Models
Phosphorylation

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Hida, Hirotake ; Mouri, Akihiro ; Mori, Kentaro ; Matsumoto, Yurie ; Seki, Takeshi ; Taniguchi, Masayuki ; Yamada, Kiyofumi ; Iwamoto, Kunihiro ; Ozaki, Norio ; Nabeshima, Toshitaka ; Noda, Yukihiro. / Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits : The complex mechanism of blonanserin action involving D3-5-HT2A and D 1-NMDA receptors in the mPFC. In: Neuropsychopharmacology. 2015 ; Vol. 40, No. 3. pp. 601-613.
@article{c515b6455e834bf4a7a4f844fd6626df,
title = "Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: The complex mechanism of blonanserin action involving D3-5-HT2A and D 1-NMDA receptors in the mPFC",
abstract = "Blonanserin differs from currently used serotonin 5-HT 2A/dopamine-D 2 receptor antagonists in that it exhibits higher affinity for dopamine-D 2/3 receptors than for serotonin 5-HT 2A receptors. We investigated the involvement of dopamine-D 3 receptors in the effects of blonanserin on cognitive impairment in an animal model of schizophrenia. We also sought to elucidate the molecular mechanism underlying this involvement. Blonanserin, as well as olanzapine, significantly ameliorated phencyclidine (PCP)-induced impairment of visual-recognition memory, as demonstrated by the novel-object recognition test (NORT) and increased extracellular dopamine levels in the medial prefrontal cortex (mPFC). With blonanserin, both of these effects were antagonized by DOI (a serotonin 5-HT 2A receptor agonist) and 7-OH-DPAT (a dopamine-D 3 receptor agonist), whereas the effects of olanzapine were antagonized by DOI but not by 7-OH-DPAT. The ameliorating effect was also antagonized by SCH23390 (a dopamine-D 1 receptor antagonist) and H-89 (a protein kinase A (PKA) inhibitor). Blonanserin significantly remediated the decrease in phosphorylation levels of PKA at Thr 197 and of NR1 (an essential subunit of N-methyl-D-aspartate (NMDA) receptors) at Ser 897 by PKA in the mPFC after a NORT training session in the PCP-administered mice. There were no differences in the levels of NR1 phosphorylated at Ser 896 by PKC in any group. These results suggest that the ameliorating effect of blonanserin on PCP-induced cognitive impairment is associated with indirect functional stimulation of the dopamine-D 1-PKA-NMDA receptor pathway following augmentation of dopaminergic neurotransmission due to inhibition of both dopamine-D 3 and serotonin 5-HT 2A receptors in the mPFC.",
author = "Hirotake Hida and Akihiro Mouri and Kentaro Mori and Yurie Matsumoto and Takeshi Seki and Masayuki Taniguchi and Kiyofumi Yamada and Kunihiro Iwamoto and Norio Ozaki and Toshitaka Nabeshima and Yukihiro Noda",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/npp.2014.207",
language = "English",
volume = "40",
pages = "601--613",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits : The complex mechanism of blonanserin action involving D3-5-HT2A and D 1-NMDA receptors in the mPFC. / Hida, Hirotake; Mouri, Akihiro; Mori, Kentaro; Matsumoto, Yurie; Seki, Takeshi; Taniguchi, Masayuki; Yamada, Kiyofumi; Iwamoto, Kunihiro; Ozaki, Norio; Nabeshima, Toshitaka; Noda, Yukihiro.

In: Neuropsychopharmacology, Vol. 40, No. 3, 01.01.2015, p. 601-613.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits

T2 - The complex mechanism of blonanserin action involving D3-5-HT2A and D 1-NMDA receptors in the mPFC

AU - Hida, Hirotake

AU - Mouri, Akihiro

AU - Mori, Kentaro

AU - Matsumoto, Yurie

AU - Seki, Takeshi

AU - Taniguchi, Masayuki

AU - Yamada, Kiyofumi

AU - Iwamoto, Kunihiro

AU - Ozaki, Norio

AU - Nabeshima, Toshitaka

AU - Noda, Yukihiro

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Blonanserin differs from currently used serotonin 5-HT 2A/dopamine-D 2 receptor antagonists in that it exhibits higher affinity for dopamine-D 2/3 receptors than for serotonin 5-HT 2A receptors. We investigated the involvement of dopamine-D 3 receptors in the effects of blonanserin on cognitive impairment in an animal model of schizophrenia. We also sought to elucidate the molecular mechanism underlying this involvement. Blonanserin, as well as olanzapine, significantly ameliorated phencyclidine (PCP)-induced impairment of visual-recognition memory, as demonstrated by the novel-object recognition test (NORT) and increased extracellular dopamine levels in the medial prefrontal cortex (mPFC). With blonanserin, both of these effects were antagonized by DOI (a serotonin 5-HT 2A receptor agonist) and 7-OH-DPAT (a dopamine-D 3 receptor agonist), whereas the effects of olanzapine were antagonized by DOI but not by 7-OH-DPAT. The ameliorating effect was also antagonized by SCH23390 (a dopamine-D 1 receptor antagonist) and H-89 (a protein kinase A (PKA) inhibitor). Blonanserin significantly remediated the decrease in phosphorylation levels of PKA at Thr 197 and of NR1 (an essential subunit of N-methyl-D-aspartate (NMDA) receptors) at Ser 897 by PKA in the mPFC after a NORT training session in the PCP-administered mice. There were no differences in the levels of NR1 phosphorylated at Ser 896 by PKC in any group. These results suggest that the ameliorating effect of blonanserin on PCP-induced cognitive impairment is associated with indirect functional stimulation of the dopamine-D 1-PKA-NMDA receptor pathway following augmentation of dopaminergic neurotransmission due to inhibition of both dopamine-D 3 and serotonin 5-HT 2A receptors in the mPFC.

AB - Blonanserin differs from currently used serotonin 5-HT 2A/dopamine-D 2 receptor antagonists in that it exhibits higher affinity for dopamine-D 2/3 receptors than for serotonin 5-HT 2A receptors. We investigated the involvement of dopamine-D 3 receptors in the effects of blonanserin on cognitive impairment in an animal model of schizophrenia. We also sought to elucidate the molecular mechanism underlying this involvement. Blonanserin, as well as olanzapine, significantly ameliorated phencyclidine (PCP)-induced impairment of visual-recognition memory, as demonstrated by the novel-object recognition test (NORT) and increased extracellular dopamine levels in the medial prefrontal cortex (mPFC). With blonanserin, both of these effects were antagonized by DOI (a serotonin 5-HT 2A receptor agonist) and 7-OH-DPAT (a dopamine-D 3 receptor agonist), whereas the effects of olanzapine were antagonized by DOI but not by 7-OH-DPAT. The ameliorating effect was also antagonized by SCH23390 (a dopamine-D 1 receptor antagonist) and H-89 (a protein kinase A (PKA) inhibitor). Blonanserin significantly remediated the decrease in phosphorylation levels of PKA at Thr 197 and of NR1 (an essential subunit of N-methyl-D-aspartate (NMDA) receptors) at Ser 897 by PKA in the mPFC after a NORT training session in the PCP-administered mice. There were no differences in the levels of NR1 phosphorylated at Ser 896 by PKC in any group. These results suggest that the ameliorating effect of blonanserin on PCP-induced cognitive impairment is associated with indirect functional stimulation of the dopamine-D 1-PKA-NMDA receptor pathway following augmentation of dopaminergic neurotransmission due to inhibition of both dopamine-D 3 and serotonin 5-HT 2A receptors in the mPFC.

UR - http://www.scopus.com/inward/record.url?scp=84922072555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922072555&partnerID=8YFLogxK

U2 - 10.1038/npp.2014.207

DO - 10.1038/npp.2014.207

M3 - Article

VL - 40

SP - 601

EP - 613

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -